Clinical trial · Interventional
A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma
A Phase II, Multicenter, Open-Label Study of YM155 in Subjects With Unresectable Stage III or Metastatic (Stage IV) Melanoma
NCT00281541CI-TRIAL-00007109completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A study with YM155 for the treatment of unresectable stage III or metastatic stage IV melanoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Melanoma | Melanoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| YM155 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Tumor response rate
- timeFrame
- 6 cycles
Secondary outcomes (1)
- measure
- Duration of response
- timeFrame
- 6 cycles
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically or cytologically confirmed unresectable stage III or IV malignant melanoma * Life expectancy \>12 weeks Exclusion Criteria: * History of other malignancy in the last 5 years * Major surgery within the past 21 days
References
Publications (0)
Data not yet available
No reference posted for this study.